Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32

Molecular Therapy

Volumn 21, Issue 12, 2013, Pages 2195-2204

  Agemy, Lilach ^a,b   Kotamraju, Venkata R ^a,b   Friedmann Morvinski, Dinorah ^c   Sharma, Shweta ^a   Sugahara, Kazuki N ^a,b   Ruoslahti, Erkki ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CYSTYLGLYCYLLYSYLARGINYLLYSINE DEXTRO LYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSYLLYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSINE PEPTIDE; MITOCHONDRIAL PROTEIN; NARDILYSIN; P32 PROTEIN; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR ASSOCIATED LEUKOCYTE;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; ORGAN SPECIFICITY; PEPTIDES; RECEPTORS, COMPLEMENT;

EID: 84890127228     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.191     Document Type: Article

References (33)

1. Ferrari, M (2010). Frontiers in cancer nanomedicine: Directing mass transport through biological barriers. Trends Biotechnol 28: 181-188
2. Ferrara, N and Alitalo, K (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364
3. Ruoslahti, E (2012). Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater Weinheim 24: 3747-3756
4. Gradishar, WJ, Tjulandin, S, Davidson, N, Shaw, H, Desai, N, Bhar, P et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803
5. Haley, B and Frenkel, E (2008). Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26: 57-64
6. Agemy, L, Friedmann-Morvinski, D, Kotamraju, VR, Roth, L, Sugahara, KN, Girard, OM et al. (2011). Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci USA 108: 17450-17455
7. Park, JH, von Maltzahn, G, Zhang, L, Derfus, AM, Simberg, D, Harris, TJ et al. (2009). Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5: 694-700
8. Joyce, JA, Laakkonen, P, Bernasconi, M, Bergers, G, Ruoslahti, E and Hanahan, D (2003). Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4: 393-403
9. Javadpour, MM, Juban, MM, Lo, WC, Bishop, SM, Alberty, JB, Cowell, SM et al. (1996). De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 39: 3107-3113
10. Ellerby, HM, Arap, W, Ellerby, LM, Kain, R, Andrusiak, R, Rio, GD et al. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038
11. Arap, W, Haedicke, W, Bernasconi, M, Kain, R, Rajotte, D, Krajewski, S et al. (2002). Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 99: 1527-1531
12. Ruoslahti, E, Bhatia, SN and Sailor, MJ (2010). Targeting of drugs and nanoparticles to tumors. J Cell Biol 188: 759-768
13. Sugahara, KN, Teesalu, T, Karmali, PP, Kotamraju, VR, Agemy, L, Girard, OM et al. (2009). Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520
14. Sugahara, KN, Teesalu, T, Karmali, PP, Kotamraju, VR, Agemy, L, Greenwald, DR et al. (2010). Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328: 1031-1035
15. Krainer, AR, Mayeda, A, Kozak, D and Binns, G (1991). Functional expression of cloned human splicing factor SF2: Homology to RNA-binding proteins, U1 70K, and Drosophila splicing regulators. Cell 66: 383-394
16. Fogal, V, Zhang, L, Krajewski, S and Ruoslahti, E (2008). Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68: 7210-7218
17. Erdreich-Epstein, A, Shimada, H, Groshen, S, Liu, M, Metelitsa, LS, Kim, KS et al. (2000). Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 60: 712-721
18. Christian, S, Pilch, J, Akerman, ME, Porkka, K, Laakkonen, P and Ruoslahti, E (2003). Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 163: 871-878
19. Basolo, F, Elliott, J, Tait, L, Chen, XQ, Maloney, T, Russo, IH et al. (1991). Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinog 4: 25-35
20. Santner, SJ, Dawson, PJ, Tait, L, Soule, HD, Eliason, J, Mohamed, AN et al. (2001). Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65: 101-110
21. Soda, Y, Marumoto, T, Friedmann-Morvinski, D, Soda, M, Liu, F, Michiue, H et al. (2011). Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 108: 4274-4280
22. Laakkonen, P, Akerman, ME, Biliran, H, Yang, M, Ferrer, F, Karpanen, T et al. (2004). Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 101: 9381-9386
23. Hamzah, J, Kotamraju, VR, Seo, JW, Agemy, L, Fogal, V, Mahakian, LM et al. (2011). Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 108: 7154-7159
24. Said, EA, Krust, B, Nisole, S, Svab, J, Briand, JP and Hovanessian, AG (2002). The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J Biol Chem 277: 37492-37502
25. Shibata, Y, Muramatsu, T, Hirai, M, Inui, T, Kimura, T, Saito, H et al. (2002). Nuclear targeting by the growth factor midkine. Mol Cell Biol 22: 6788-6796
26. Laakkonen, P, Porkka, K, Hoffman, JA and Ruoslahti, E (2002). A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8: 751-755
27. Hoffman, JA, Giraudo, E, Singh, M, Zhang, L, Inoue, M, Porkka, K et al. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4: 383-391
28. Roth, L, Agemy, L, Kotamraju, VR, Braun, G, Teesalu, T, Sugahara, KN et al. (2012). Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 31: 3754-3763
29. Teesalu, T, Sugahara, KN, Kotamraju, VR and Ruoslahti, E (2009). C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106: 16157-16162
30. Standley, SM, Toft, DJ, Cheng, H, Soukasene, S, Chen, J, Raja, SM et al. (2010). Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. Cancer Res 70: 3020-3026
31. Marumoto, T, Tashiro, A, Friedmann-Morvinski, D, Scadeng, M, Soda, Y, Gage, FH et al. (2009). Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15: 110-116
32. Dull, T, Zufferey, R, Kelly, M, Mandel, RJ, Nguyen, M, Trono, D et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471
33. Ikawa, M, Tanaka, N, Kao, WW and Verma, IM (2003). Generation of transgenic mice using lentiviral vectors: A novel preclinical assessment of lentiviral vectors for gene therapy. Mol Ther 8: 666-673